Document Classification

Section Type: RESULTS

Text: Patients randomized to adjuvant gemcitabine treatment had prolonged overall survival compared with those randomized to observation alone (hazard ratio, 0. 76 [95 % CI, 0. 61-0. 95] ; P =. 01), with 5-year overall survival of 20. 7 % (95 % CI, 14. 7 % -26. 6 %) vs 10. 4 % (95 % CI, 5. 9 % -15. 0 %), respectively, and 10-year overall survival of 12. 2 % (95 % CI, 7. 3 % -17. 2 %) vs 7. 7 % (95 % CI, 3. 6 % -11. 8 %).